ENTA does not receive a milestone payment from ABBV for Maviret approval in Canada, but ENTA does get a $15M milestone payment from ABBV for approval in Japan, which is expected in the next two quarters.
*Note spelling, which is the same as the brand name in the EU but differs from the “Mavyret” brand name in the US.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.